Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers (I-NET)
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase I Study of Nelfinavir in Combination With Temsirolimus in the Treatment of Patients With Advanced Cancers, Including Second Line Renal Cell Cancer|
- Pharmacokinetics/pharmacodynamics [ Time Frame: During the first 5 weeks of treatment ] [ Designated as safety issue: No ]PK Nelfinavir: D1, 11, 18, 25, 32 PK Temsirolimus: D4, 11, 18, 25,32
- Toxicity profile [ Time Frame: Day1 -Day90 ] [ Designated as safety issue: Yes ]Collection of clinical data according to CTC toxicity criteria
- Objective response to treatment [ Time Frame: Expected treatment duration: 2-12 months ] [ Designated as safety issue: No ]Progress-scans once every 9 weeks will be performed
- Description and change of Biomarker analysis/Pharmacodynamics [ Time Frame: Day 1, 18, 25 ] [ Designated as safety issue: No ]Blood biomarker analysis will be performed of PBMCs and where possible of tumor biposies performed during treatment
- Pharmacogenetics [ Time Frame: day 1 of treatment ] [ Designated as safety issue: No ]Full blood sample will be collected for pharmacogenetic analysis of important SNPs of drug disposition genes involved in the drug disposition of Nelfinivar and temsirolimus
|Study Start Date:||June 2009|
|Study Completion Date:||August 2011|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
Experimental: nelfinavir and temsirolimus
Drug: Nelfinavir and temsirolimus
Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
Other Name: nelfinavir: viracept
In the past decade, the characterization of human tumours at the molecular level has considerably improved. This has led to the development of targeted therapeutics that inhibit specific molecules and pathways involved in oncogenesis. One of the key pathways that is dysregulated in cancer is the phosphatidylinositol 3'-kinase (PI3K)/Akt/mTOR pathway. This pathway is important for cell growth and survival. In most cancer types this pathway is over-activated leading to proliferation and survival of malignant cells. Inhibition of this pathway is therefore of great therapeutic potential.
Both temsirolimus and nelfinavir are agents with PI3K /Akt/mTOR inhibiting activity. The main active metabolite of temsirolimus is sirolimus that decreases mTOR activity. Inhibition of mTOR activity results in G1 phase cell cycle arrest and subsequent inhibition of tumour growth. Another effect is growth factor downregulation and inhibition of angiogenesis. In addition, mTOR inhibition may exert its anti-tumour effect by inducing apoptosis.
Although inhibitors of mTOR demonstrated clinical activity in tumor types like, mantle cell lymphoma, endometrial carcinoma, and neuro-endocrine tumors, most malignancies are resistant by feedback PI3 kinase activation. Resent data suggest that this tumor escape mechanism can be overcome by dual inhibition of mTOR and PI3 kinase.
Nelfinavir is a well known human immuno-deficiency protease inhibitor with PI3kinase inhibiting activity, via inhibition of Akt, downstream the PI3kinase cascade. Nelfinavir is able to inhibit Akt at concentrations that are achieved in HIV patients at standard antiviral doses. Nelfinavir is therefore a feasable and generally well tolerated agent to be used in combination with temsirolimus to overcome resistance of mTOR inhibition.
Simultaneous inhibition of mTOR/PI3kinase pathway by temsirolimus and nelfinavir is a promising strategy to treat cancer.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01079286
|Academic Medical Center|
|Amsterdam, Netherlands, 1105AZ|
|Principal Investigator:||Heinz-Josef Klumpen, MD||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|